A 24-week, Multicentre, Randomised, Double-blind, Age-stratified, Placebo Controlled, Phase III Study With a 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin 10 mg Once Daily in Pts With T2DM, CV Disease and Hypertension Who Exhibit Inadequate Glycaemic Control on Usual Care
Overview
- Phase
- Phase 3
- Intervention
- Dapagliflozin
- Conditions
- Type 2 Diabetes Mellitus
- Sponsor
- AstraZeneca
- Enrollment
- 922
- Locations
- 1
- Primary Endpoint
- Adjusted Mean Change in HbA1c Levels
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
This study is carried out to assess whether dapagliflozin lowers blood glucose, body weight and blood pressure, when added to patients existing medications and how it compares with their usual treatment without added dapagliflozin. Safety data will be collected and analysed to confirm that treatment with dapagliflozin is safe and well tolerated in patients who have diabetes, cardiovascular disease and hypertension.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Type 2 diabetes mellitus.
- •Cardiovascular disease
- •Hypertension
Exclusion Criteria
- •Patients with type 1 diabetes or diabetes insipidus
- •Patients with 3 or more oral anti-hyperglycaemic drugs with or without insulin and/or poorly controlled diabetes
- •Any clinically significant illness, which would compromise the patient's safety and their participation in the study
Arms & Interventions
1
Dapagliflozin 10 mg tablet
Intervention: Dapagliflozin
2
Matching placebo tablet
Intervention: Placebo
Outcomes
Primary Outcomes
Adjusted Mean Change in HbA1c Levels
Time Frame: Baseline to Week 24
To compare the glycemic efficacy of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease and hypertension, measured as the mean change in HbA1c from baseline to week 24.
Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit
Time Frame: Baseline to week 24
To compare the clinical benefit of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease and hypertension at week 24, measured as the proportion of responders for a 3-item endpoint of clinical benefit, defined as an absolute drop of 0.5% or more from baseline HbA1c, and a relative drop of 3% or more from baseline for total body weight, and an absolute drop of 3 mmHg or more from baseline in seated systolic blood pressure.
Secondary Outcomes
- Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 24 (LOCF)(Baseline to Week 24)
- Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI ≥27 kg/m²(Baseline to Week 24)
- Adjusted Mean Percent Change in Body Weight(Baseline to Week 24)
- Adjusted Mean Change in Seated Systolic Blood Pressure (SBP)(Baseline to Week 8)